Report Description Table of Contents How Is the Gestational Diabetes Market Evolving Through Prenatal Screening, Glucose Monitoring, and Maternal Healthcare Advancements? – (Updated On: 10th-Nov-2026) According to Strategic Market Research, the Global Gestational Diabetes Market was valued at USD 7.77 billion in 2025 and is projected to reach USD 13.08 billion by 2032, growing at a CAGR of 7.7% during 2026–2032. The projected USD 5.31 billion increase in annual market revenue is supported by rising gestational diabetes diagnoses, expanding prenatal screening, increasing glucose monitoring requirements, and demand for pregnancy-specific diabetes treatment. Growth opportunities extend across diagnostic testing, blood glucose monitoring devices, continuous glucose monitoring systems, insulin therapies, and specialized maternal healthcare services. The increasing global burden of hyperglycemia during pregnancy is creating a substantial patient base for gestational diabetes diagnosis and management. According to the International Diabetes Federation's Diabetes Atlas (2025), approximately 23.0 million live births worldwide were affected by hyperglycemia during pregnancy in 2024, representing 19.7% of global live births. Gestational diabetes accounted for 79.2% of these cases, equivalent to approximately 18.2 million affected live births. The high disease burden supports demand for prenatal glucose screening, diagnostic laboratory services, home monitoring devices, and specialist maternal healthcare. These requirements create recurring revenue opportunities for diagnostic manufacturers and diabetes care providers. The United States represents an important market for pregnancy-related glucose testing and treatment. A study published in JAMA Internal Medicine in December 2025, based on National Center for Health Statistics birth records, reported that the age-standardized gestational diabetes rate increased from 58.2 per 1,000 live births in 2016 to 79.3 per 1,000 live births in 2024. The increase reflects a growing diagnosed patient population requiring glucose assessment and pregnancy-specific diabetes management. This trend supports demand for diagnostic laboratories, glucose meters, monitoring consumables, and insulin therapies. Expanding prenatal screening recommendations are supporting recurring demand for glucose diagnostic services. The American Diabetes Association's 2026 Standards of Care emphasize early assessment of women at increased metabolic risk, routine gestational diabetes screening, and postpartum testing. These recommendations strengthen the role of oral glucose tolerance tests, glucose challenge tests, fasting plasma glucose assessments, and associated laboratory consumables in maternal healthcare. Screening requirements also create opportunities for diagnostic laboratories and healthcare providers offering integrated antenatal services. Insulin treatment remains an important revenue-generating category because some women cannot achieve recommended glucose levels through nutritional management and physical activity alone. The ADA's 2026 recommendations identify insulin as the preferred pharmacological treatment when lifestyle interventions are insufficient. The guidelines also highlight concerns regarding the placental transfer of oral antidiabetic medications such as metformin and glyburide. This supports the commercial position of insulin manufacturers while creating demand for pregnancy-specific medication management and glucose monitoring. Regular blood glucose monitoring creates recurring demand for meters, test strips, lancets, and continuous glucose monitoring systems throughout pregnancy. Healthcare professionals use fasting and post-meal glucose measurements to assess treatment effectiveness and adjust management plans. The ADA recommends pregnancy-specific glucose targets, including fasting glucose below 95 mg/dL and either one-hour post-meal glucose below 140 mg/dL or two-hour post-meal glucose below 120 mg/dL. These requirements support demand for home monitoring devices and connected diabetes management solutions. Continuous glucose monitoring is creating additional commercial opportunities in pregnancy-related diabetes management. A randomized controlled trial published in Diabetes Care in 2025 evaluated 111 pregnant women with gestational diabetes. Participants using real-time CGM alongside conventional blood glucose testing achieved an average glucose time-in-range of 93%, compared with 88% among participants using conventional monitoring alone. The findings support the potential clinical value of continuous monitoring, although further research is needed to establish improvements in maternal and neonatal outcomes. This creates opportunities for wearable sensor manufacturers, mobile health platforms, and remote maternal care providers. Product developments are also expanding the availability of pregnancy-compatible glucose monitoring solutions. Dexcom offers its G7 continuous glucose monitoring system for use during pregnancy, including among women with gestational diabetes. Abbott's FreeStyle Libre 2 and Libre 3 systems are also included in the ADA's 2026 Diabetes Technology Standards as products with pregnancy indications. These developments strengthen opportunities for wearable glucose monitoring, mobile applications, and remote data-sharing services. However, CGM devices support glucose monitoring and should not be considered replacements for established diagnostic procedures such as OGTT. Competition in the gestational diabetes market includes companies supplying glucose monitoring technologies, diagnostic products, insulin therapies, and connected diabetes management solutions. Abbott Laboratories participates through its FreeStyle Libre portfolio and broader Diabetes Care business. Dexcom offers pregnancy-compatible continuous glucose monitoring systems, while Medtronic participates through diabetes monitoring and insulin delivery technologies. Roche Diabetes Care supplies Accu-Chek blood glucose monitoring products. Novo Nordisk, Eli Lilly, and Sanofi participate through insulin products used in pregnancy when clinically appropriate. Commercial opportunities are concentrated in products supporting regular glucose assessment, treatment adherence, and coordinated maternal care. The Gestational Diabetes Market is expected to expand through 2032 as more pregnancies undergo glucose screening and diagnosed patients require continuous monitoring and treatment. The number of affected pregnancies, diagnostic coverage, insulin utilization, monitoring frequency, and availability of pregnancy-compatible glucose technologies will influence market revenue. Asia-Pacific offers substantial expansion potential because of its maternal healthcare requirements, while established healthcare systems in North America and Europe support demand for advanced monitoring and specialist treatment. Which Segments Are Leading the Gestational Diabetes Market, and Where Are the Strongest Commercial Opportunities Emerging? By Treatment Type: Lifestyle Support Comes First as Insulin Fills the Glucose Control Gap Leading Segment: Diet and Lifestyle Management Diet and Lifestyle Management maintains the leading position in the Gestational Diabetes Market because nutritional counseling, controlled carbohydrate intake, and physical activity form the foundation of pregnancy-related diabetes care. Healthcare providers generally begin management with lifestyle interventions and introduce medication when glucose levels remain above recommended targets. This creates opportunities for maternal nutrition programs, specialized dietary counseling, pregnancy-focused healthcare services, and glucose management platforms. Fastest-Growing Segment: Insulin Therapy and Diet and Lifestyle Management (Joint) Insulin Therapy and Diet and Lifestyle Management are jointly positioned among the fastest-growing treatment categories based on the supplied market estimates. Their expansion reflects the complementary role of nutritional interventions and medication-based glucose management. Increasing attention to pregnancy-specific glucose targets and the need for individualized treatment plans support demand for insulin products, dietary programs, and coordinated maternal diabetes care. By Product Type: Routine Meter Use Sustains Consumable Demand as Wearable Monitoring Expands Leading Segment: Blood Glucose Monitoring Devices Blood glucose monitoring devices maintain their leading position because they support routine assessment of fasting and post-meal glucose levels. Their established use in prenatal diabetes management supports recurring demand for glucose meters, test strips, lancets, and replacement supplies. Manufacturers with affordable products and reliable distribution networks can benefit from continued use of home-based monitoring. Fastest-Growing Segment: Continuous Glucose Monitoring Systems Continuous Glucose Monitoring Systems are gaining importance because they provide more frequent glucose information than conventional intermittent testing. Wearable sensors and connected applications help patients and healthcare professionals identify glucose fluctuations and review monitoring patterns. The expansion of pregnancy indications for selected CGM products creates opportunities for manufacturers to develop maternal healthcare partnerships and connected monitoring services. By Diagnosis Method: Glucose Tolerance Testing Anchors Diagnosis as Fasting Tests Support Earlier Assessment Leading Segment: Oral Glucose Tolerance Test (OGTT) OGTT maintains its dominant position because it is an established diagnostic approach for identifying gestational glucose intolerance. Its use in prenatal screening pathways supports recurring demand for glucose solutions, laboratory testing, sample collection products, and diagnostic services. Laboratories with established maternity healthcare relationships are positioned to benefit from continued screening requirements. Fastest-Growing Segment: Fasting Plasma Glucose Test Fasting Plasma Glucose Testing offers opportunities in early pregnancy metabolic assessment and selected diagnostic protocols. Increasing attention to identifying previously undiagnosed diabetes before routine gestational screening supports its use in maternal healthcare. Its commercial potential is linked to laboratory testing coverage, early prenatal consultations, and follow-up diagnostic services. By Distribution Channel: Hospital Pharmacies Coordinate Treatment as Online Channels Ease Replenishment Leading Segment: Hospital Pharmacies Hospital pharmacies maintain their leading position through their involvement in medication dispensing, insulin management, and coordination with obstetric and endocrinology departments. Their integration with maternity services supports access to prescribed treatments and glucose monitoring supplies. Hospitals with established maternal diabetes programs are important purchasing channels for pharmaceutical and diagnostic suppliers. Fastest-Growing Segment: Online Pharmacies Online pharmacies are strengthening access to glucose monitoring supplies, prescribed medicines, and pregnancy-related diabetes products. Digital prescription management, home delivery, and convenient replenishment support their expansion. Opportunities are particularly relevant for suppliers offering recurring consumables and reliable distribution services, although prescription regulations and reimbursement arrangements will influence adoption. By End User: Maternity Centers Coordinate High-Risk Care as Monitoring Extends Into the Home Leading Segment: Hospitals and Maternity Centers Hospitals and maternity centers maintain their leading position through their involvement in prenatal screening, specialist consultations, diagnosis, and treatment of high-risk pregnancies. Their multidisciplinary services support demand for diagnostic tests, glucose monitoring devices, insulin products, and maternal healthcare programs. Integration between obstetricians, endocrinologists, laboratory departments, and pharmacists strengthens their commercial importance. Fastest-Growing Segment: Homecare Settings Homecare settings are gaining importance as pregnancy-related glucose management increasingly extends beyond hospital visits. Home glucose meters, wearable sensors, connected applications, and remote consultations support monitoring between prenatal appointments. This creates opportunities for device manufacturers, digital health providers, and suppliers of recurring glucose testing consumables. By Geography: Established North American Screening and Wider Access in Asia-Pacific Shape Growth Leading Region: North America North America maintains its leading position through established prenatal screening practices, advanced diagnostic infrastructure, and access to diabetes management technologies. The United States and Canada offer commercial opportunities for glucose monitoring manufacturers, diagnostic laboratories, and pharmaceutical companies supplying insulin products. Established healthcare reimbursement systems and specialist maternal care services support market development. Fastest-Growing Region: Asia-Pacific Asia-Pacific offers significant expansion opportunities because of its large maternal population and increasing attention to pregnancy-related metabolic disorders. A nationally representative ICMR-INDIAB study published in the Indian Journal of Medical Research in 2025 estimated India's weighted gestational diabetes prevalence at 22.4% among the women assessed. The study also identified regional variation, with Central India recording 32.9% prevalence. These findings highlight opportunities for affordable OGTT products, laboratory testing, glucose meters, and maternal diabetes screening services across India. China, Japan, and Australia also offer opportunities through established and expanding maternal healthcare infrastructure. Which Companies Are Shaping the Gestational Diabetes Market Through Glucose Monitoring, Insulin Therapy, and Maternal Healthcare Innovation? Abbott Laboratories: FreeStyle Libre Expands Its Reach in Maternal Glucose Monitoring Abbott Laboratories is a major participant in the gestational diabetes market through its FreeStyle Libre continuous glucose monitoring portfolio and broader blood glucose monitoring solutions. The company's wearable glucose sensors and connected monitoring platforms support glucose assessment and diabetes management. Its FreeStyle Libre products with pregnancy indications strengthen its position in the maternal glucose monitoring segment. Abbott's financial performance demonstrates the commercial scale of its diabetes monitoring business. According to its January 2026 financial results, Abbott reported approximately USD 8.0 billion in global Diabetes Care sales for full-year 2025, representing reported growth of 17.5% compared with 2024. The business includes its continuous glucose monitoring portfolio and other diabetes care products. These results demonstrate the commercial strength of its broader glucose monitoring business, although the reported revenue covers multiple diabetes populations and does not represent gestational diabetes-specific sales. Other Key Companies and Their Roles: Dexcom: Offers the G7 continuous glucose monitoring system, which can be used during pregnancy, including among women with gestational diabetes. Its connected monitoring and data-sharing capabilities support glucose management and communication between patients and healthcare professionals. Novo Nordisk: Supplies insulin therapies, including established insulin formulations used in pregnancy-related diabetes management under medical supervision. Eli Lilly and Company: Provides insulin products and diabetes treatment expertise relevant to pregnant patients requiring medication-based glucose control. Medtronic: Develops continuous glucose monitoring systems, insulin delivery technologies, and connected diabetes management solutions. F. Hoffmann-La Roche Ltd: Offers Accu-Chek blood glucose monitoring systems, testing supplies, and digital diabetes management solutions supporting routine glucose monitoring. Sanofi: Participates in the diabetes therapeutics market through insulin products used in pregnancy when clinically appropriate. What Are the Key Factors Driving the Gestational Diabetes Market Across Prenatal Screening, Glucose Monitoring, and Maternal Healthcare? 1. Rising Prevalence of Gestational Diabetes and Maternal Health Risk Factors The increasing prevalence of gestational diabetes, maternal obesity, insulin resistance, and pregnancies at advanced maternal ages is supporting demand for pregnancy-related diabetes diagnosis and treatment. Women with previous gestational diabetes, a family history of diabetes, or elevated pre-pregnancy body weight may require closer metabolic assessment during subsequent pregnancies. The growing clinical burden creates opportunities for prenatal glucose screening, diagnostic consumables, home monitoring devices, and specialist maternal healthcare services. Healthcare providers are also increasing their focus on identifying women with metabolic risk factors before pregnancy and during early antenatal consultations. This supports demand for preventive screening and pregnancy-specific diabetes management programs. 2. Expanding Prenatal Screening and Early Diagnosis Programs The integration of diabetes screening into routine antenatal care is supporting utilization of diagnostic tests and laboratory services. The ADA's 2026 Standards of Care recommend screening for gestational diabetes between 24 and 28 weeks in pregnant women not previously diagnosed with diabetes. Earlier testing is recommended for identifying previously undiagnosed diabetes and abnormal glucose metabolism in women with relevant risk factors. The guidelines also recommend postpartum screening between 4 and 12 weeks for women with a history of gestational diabetes, followed by lifelong screening every 1–3 years. This extends diagnostic demand beyond the pregnancy period and creates additional opportunities for glucose testing manufacturers, diagnostic laboratories, and healthcare providers. A further development emerged in September 2026, when the World Health Organization convened its guideline development group to review recommendations concerning the criteria and diagnosis of hyperglycemia during pregnancy. The review highlights the importance of improving diagnostic consistency and access to maternal screening, particularly in healthcare systems with limited resources. This could influence future diagnostic protocols and create opportunities for manufacturers offering affordable glucose testing solutions. 3. Advancements in Continuous Glucose Monitoring and Digital Maternal Care Technological improvements in glucose monitoring are strengthening opportunities for connected medical devices and remote pregnancy management. Wearable glucose sensors, smartphone-connected applications, and digital health platforms help healthcare professionals evaluate glucose fluctuations and review patient monitoring data. The expansion of pregnancy indications for selected CGM systems is also creating commercial opportunities for manufacturers. Abbott and Dexcom are strengthening their positions through wearable monitoring products, while healthcare providers are increasingly exploring remote glucose data-sharing and digital maternal care services. Companies combining monitoring devices with patient support and clinical data platforms can strengthen their presence in pregnancy-related diabetes management. 4. Increasing Clinical Focus on Preventing Maternal and Neonatal Complications Healthcare providers are placing greater emphasis on maintaining appropriate maternal glucose levels to reduce pregnancy-related complications. Hyperglycemia during pregnancy is associated with hypertensive disorders, excessive fetal growth, stillbirth, neonatal hypoglycemia, and birth injuries. The World Health Organization's 2025 guideline development initiative highlighted the need to improve the monitoring and management of hyperglycemia during pregnancy. This reinforces the importance of early diagnosis, appropriate treatment, and coordinated maternal healthcare. The commercial implications extend across diagnostic companies, glucose monitoring manufacturers, insulin suppliers, and healthcare providers offering specialized pregnancy management services. Analyst Commentary: Where Can Suppliers Grow as Prenatal Screening and Glucose Monitoring Expand? The strongest commercial opportunities in the gestational diabetes market lie in affordable prenatal diagnostics, recurring glucose monitoring supplies, and pregnancy-compatible continuous monitoring systems. Companies combining clinically supported products with accessible maternal healthcare and remote monitoring services can strengthen their competitive position, particularly across high-burden Asia-Pacific markets. Clinical evidence, reimbursement, and access to prenatal screening will remain important factors determining adoption. Gestational Diabetes Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 7.77 Billion Revenue Forecast in 2032 USD 13.08 Billion Overall Growth Rate CAGR of 7.7% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Treatment Type, By Product Type, By Diagnosis Method, By Distribution Channel, By End User, By Geography By Treatment Type Diet and Lifestyle Management, Insulin Therapy, Oral Antidiabetic Medications By Product Type Blood Glucose Monitoring Devices, Continuous Glucose Monitoring Systems, Diagnostic Test Kits and Consumables, Antidiabetic Medications By Diagnosis Method Oral Glucose Tolerance Test, Glucose Challenge Test, Fasting Plasma Glucose Test By Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies By End User Hospitals and Maternity Centers, Diabetes and Endocrinology Clinics, Diagnostic Laboratories, Homecare Settings By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Rising gestational diabetes diagnoses, expanded prenatal glucose screening, repeat glucose monitoring throughout pregnancy, and insulin use when diet and lifestyle measures are insufficient Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are driving growth across the market? A1. Growth is supported by rising gestational diabetes diagnoses, broader prenatal screening, recurring glucose monitoring, insulin use, and increasing demand for specialized maternal care. Q2. What technology trends are shaping the industry? A2. The industry is moving toward continuous glucose monitoring, connected sensors, mobile health platforms, and remote data-sharing tools that support more frequent glucose assessment during pregnancy. Q3. Why are continuous glucose monitoring systems gaining importance in the market? A3. Continuous glucose monitoring systems are projected to record the fastest product-type CAGR of 12.53% during 2026–2032. Pregnancy-compatible sensors and real-time glucose tracking are supporting wider adoption. Q4. Which diagnostic method offers the strongest growth opportunity in the industry? A4. Fasting plasma glucose testing is projected to record the fastest diagnosis-method CAGR of 9.45% during 2026–2032. Its role in early pregnancy risk assessment and selected diagnostic pathways supports growth. Q5. Which end-user segment is expected to expand the fastest? A5. Homecare settings are projected to record the fastest end-user CAGR of 10.88% during 2026–2032. Self-monitoring devices, wearable sensors, and remote clinical supervision are supporting this shift. Q6. Which region is expected to record the fastest growth in the market? A6. Asia-Pacific is projected to record the fastest regional CAGR of 9.59% during 2026–2032. Growth is supported by expanding prenatal screening, maternal healthcare access, and diabetes diagnostic services across major regional markets. Sources: International Diabetes Federation – Gestational Diabetes Accounted for an Estimated 18.2 Million Affected Live Births Worldwide in 2024. IDF Diabetes Atlas, 11th Edition – Hyperglycemia in Pregnancy, Table 3.16 U.S. National Center for Health Statistics Birth Records – Gestational Diabetes Rose From 58.2 to 79.3 per 1,000 First Singleton Live Births From 2016 to 2024. JAMA Internal Medicine – Gestational Diabetes in the US From 2016 to 2024 · CDC – Gestational Diabetes in the United States Indian Council of Medical Research – Weighted Gestational Diabetes Prevalence Was 22.4% Nationally, With 32.9% Reported in Central India. Indian Journal of Medical Research – ICMR-INDIAB National Study on Gestational Diabetes Prevalence American Diabetes Association and NIH – Prenatal Screening at 24–28 Weeks Supports Demand for Glucose Challenge and Oral Glucose Tolerance Testing. ADA – 2026 Diagnosis and Classification Standards · NIH/NIDDK – Tests and Diagnosis for Gestational Diabetes American Diabetes Association – Insulin Is the Preferred Medication When Lifestyle Measures Alone Are Insufficient. ADA – 2026 Standards for Management of Diabetes in Pregnancy World Health Organization – November 2025 Global Guidelines Recommend Metformin or Insulin When Diet and Physical Activity Alone Provide Insufficient Glucose Control. WHO – Recommendations on Care for Women With Diabetes During Pregnancy World Health Organization – September 2026 Announcement Set an October 20–24 Review of Pregnancy Hyperglycemia Screening and Diagnostic Criteria. WHO – Planned Update to Screening and Diagnostic Criteria for Hyperglycemia in Pregnancy Diabetes Care – Real-Time CGM Users Spent 93% of Time in the Target Glucose Range Versus 88% With Fingerstick Monitoring Alone. Diabetes Care – Randomized Trial of Real-Time CGM in Gestational Diabetes The Lancet Diabetes & Endocrinology – 2026 GRACE Trial Reported Large-for-Gestational-Age Births in 4% With Real-Time CGM Versus 10% With Fingerstick Monitoring. U.S. National Library of Medicine – GRACE Multinational Randomized Trial Dexcom and U.S. FDA – G7 15 Day Extended Sensor Wear to 15 Days for Adults and Launched in the U.S. in December 2025. FDA – G7 15 Day 510(k) Decision Summary, K243214 · Dexcom – CGM Use During Pregnancy Abbott – U.S. FreeStyle Libre Portfolio Shifted to 15-Day Plus Sensors. Abbott – U.S. FreeStyle Libre Sensor Transition · Abbott – Pharmacist Guide to FreeStyle Libre 3 Plus Abbott and U.S. SEC – Abbott Reported USD 7.998 Billion in Global Diabetes Care Sales in 2025, Up 17.5%. U.S. SEC – Abbott Fourth-Quarter and Full-Year 2025 Results Medtronic – Completed the Separation of MiniMed on October 15, 2026. Medtronic – Completion of MiniMed Group Separation Roche Diabetes Care – Accu-Chek Guide Pairs a Fingerstick Meter With Recurring Test-Strip Supplies. Roche – Accu-Chek Guide Meter · Roche – Accu-Chek Guide Test Strips Novo Nordisk, Eli Lilly, and Sanofi – U.S. Prescribing Information Covers Pregnancy Considerations for NovoLog, Humalog, and Lantus. Novo Nordisk – NovoLog Prescribing Information · DailyMed – Eli Lilly Humalog Label · Sanofi – Lantus Prescribing Information Table of Contents - Global Gestational Diabetes Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Product Type, Diagnosis Method, Distribution Channel, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Product Type, Diagnosis Method, Distribution Channel, End User, and Region Global Hyperglycemia During Pregnancy Burden and Gestational Diabetes Diagnosis Trends (2024–2025) Maternal Glucose Screening and Management Recommendations (2026) Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Product Type, Diagnosis Method, and End User Competitive Positioning Across Glucose Monitoring, Diagnostic Testing, and Insulin Therapy Investment Opportunities in the Gestational Diabetes Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Prenatal Glucose Screening and Diagnostic Laboratory Services Opportunities in Blood Glucose Monitoring Devices and Test Consumables Continuous Glucose Monitoring Systems and Pregnancy-Compatible Wearable Sensors Insulin Therapies and Pregnancy-Specific Medication Management Connected Diabetes Management, Remote Monitoring, and Digital Maternal Healthcare Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Global Burden of Hyperglycemia During Pregnancy Gestational Diabetes Prevalence and Maternal Healthcare Requirements Strategic Importance of Prenatal Screening, Glucose Monitoring, Insulin Treatment, and Postpartum Testing Role of Maternal Healthcare Providers, Diagnostic Laboratories, and Diabetes Care Companies Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Historical Market Assessment (2019–2024) Base Year Market Assessment (2025) Forecast Modeling and Assumptions (2026–2032) Market Dynamics Key Market Drivers Rising Gestational Diabetes Diagnoses and Maternal Hyperglycemia Burden Expansion of Prenatal Screening and Early Pregnancy Risk Assessment Recurring Demand for Blood Glucose Monitoring Devices and Consumables Insulin Utilization When Lifestyle Interventions Are Insufficient Increasing Adoption of Continuous Glucose Monitoring and Connected Healthcare Challenges and Restraints Impacting Growth Clinical and Regulatory Considerations for Pregnancy-Related Glucose Monitoring Emerging Opportunities for Stakeholders Impact of Maternal Healthcare Guidelines and Public Health Recommendations (2025–2026) Role of Postpartum Glucose Testing and Long-Term Diabetes Screening Diagnostic Accuracy, Treatment Adherence, and Access to Maternal Diabetes Care Global Gestational Diabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Diet and Lifestyle Management Insulin Therapy Oral Antidiabetic Medications Market Analysis by Product Type: Blood Glucose Monitoring Devices Continuous Glucose Monitoring Systems Diagnostic Test Kits and Consumables Antidiabetic Medications Market Analysis by Diagnosis Method: Oral Glucose Tolerance Test (OGTT) Glucose Challenge Test (GCT) Fasting Plasma Glucose Test Market Analysis by Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Market Analysis by End User: Hospitals and Maternity Centers Diabetes and Endocrinology Clinics Diagnostic Laboratories Homecare Settings Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Gestational Diabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Product Type, Diagnosis Method, Distribution Channel, and End User Prenatal Screening and Pregnancy-Related Glucose Testing Trends Blood Glucose Monitoring and Continuous Glucose Monitoring Adoption Country-Level Breakdown: United States Canada Mexico Europe Gestational Diabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Product Type, Diagnosis Method, Distribution Channel, and End User Organized Maternity Healthcare and Prenatal Diagnostic Pathways Insulin Treatment and Glucose Monitoring Technology Adoption Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific Gestational Diabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Product Type, Diagnosis Method, Distribution Channel, and End User Expanding Prenatal Screening and Maternal Diabetes Diagnostic Services Glucose Monitoring Access and Pregnancy-Specific Treatment Adoption Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Gestational Diabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Product Type, Diagnosis Method, Distribution Channel, and End User Maternal Healthcare Access and Prenatal Glucose Screening Services Availability of Diagnostic Testing and Home Glucose Monitoring Supplies Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa Gestational Diabetes Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Product Type, Diagnosis Method, Distribution Channel, and End User Maternal Diabetes Screening and Specialized Pregnancy Care Access to Glucose Monitoring Devices, Diagnostic Testing, and Insulin Therapy Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Abbott Laboratories Dexcom, Inc. Medtronic plc Roche Diabetes Care Novo Nordisk A/S Eli Lilly and Company Sanofi S.A. Johnson & Johnson Siemens Healthineers AG F. Hoffmann-La Roche Ltd. Ascensia Diabetes Care Terumo Corporation ARKRAY, Inc. BD (Becton, Dickinson and Company) Competitive Landscape and Strategic Insights Benchmarking Based on Glucose Monitoring Portfolios, Diagnostic Capabilities, Insulin Products, Pregnancy Indications, and Regional Presence Continuous Glucose Monitoring Product Positioning and Pregnancy-Compatible Technologies Blood Glucose Meter, Test Strip, and Monitoring Consumable Portfolio Analysis Insulin Therapy Portfolio and Pregnancy-Specific Treatment Positioning Diagnostic Testing Capabilities Across OGTT, GCT, and Fasting Plasma Glucose Testing Connected Diabetes Management and Remote Maternal Care Strategies Product Development and Innovation Trends (2025–2026) Appendix Abbreviations and Terminologies Used in the Report References and Sources Clinical Guidelines and Maternal Healthcare Recommendations (2025–2026) Market Definitions and Segmentation Classification Research Assumptions and Forecast Methodology (2026–2032) List of Tables Market Size by Treatment Type, Product Type, Diagnosis Method, Distribution Channel, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Analysis (2025), and Forecast (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Breakdown Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Leading Gestational Diabetes Market Participants Blood Glucose Monitoring and Continuous Glucose Monitoring Product Comparison Diagnostic Testing Methods and Prenatal Screening Pathways Insulin Therapy and Pregnancy-Specific Medication Management Analysis Maternal Healthcare Guidelines and Postpartum Screening Recommendations (2026) List of Figures Market Drivers, Challenges, Opportunities, and Restraints Global Gestational Diabetes Market Ecosystem and Value Chain Analysis Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type, Product Type, Diagnosis Method, Distribution Channel, and End User (2025 vs. 2032) Global Distribution of Hyperglycemia During Pregnancy and Gestational Diabetes (2024) Gestational Diabetes Screening and Management Pathway Continuous Glucose Monitoring and Connected Maternal Healthcare Adoption Regional Market Comparison Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa